drug

Preladenant

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Merck Sharp & Dohme LLC
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
NCT00686699Phase 2Terminated

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Merck Sharp & Dohme LLC
company
trial
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
PHASE2
trial
indication
Akathisia, Drug-Induced
indication
Dyskinesia, Drug-Induced
indication
Dyskinesia, Drug-Induced
indication
Akathisia, Drug-Induced
indication